{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:40:11Z","timestamp":1778866811980,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Young Scientists","award":["15K18881"],"award-info":[{"award-number":["15K18881"]}]},{"name":"Scientific Research","award":["17K08320"],"award-info":[{"award-number":["17K08320"]}]},{"name":"Scientific Research","award":["16K08278"],"award-info":[{"award-number":["16K08278"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejphar.2017.06.010","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T22:15:12Z","timestamp":1496960112000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro"],"prefix":"10.1016","volume":"810","author":[{"given":"Aya","family":"Yamamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Fujitomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikuo","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.06.010_bib1","doi-asserted-by":"crossref","first-page":"L1051","DOI":"10.1152\/ajplung.2001.281.5.L1051","article-title":"sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension","volume":"281","author":"Black","year":"2001","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib2","first-page":"151","article-title":"Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy","volume":"2","author":"Buckley","year":"2010","journal-title":"Drug Healthc. Patient Saf."},{"key":"10.1016\/j.ejphar.2017.06.010_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/CIRCRESAHA.107.161463","article-title":"Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells","volume":"102","author":"Farrow","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2017.06.010_bib4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/pr.111.005587","article-title":"The pharmacological treatment of pulmonary arterial hypertension","volume":"64","author":"Frumkin","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2017.06.010_bib5","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.06.010_bib6","first-page":"L931","article-title":"Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity","volume":"275","author":"Hanson","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib7","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1464-410X.2010.09270.x","article-title":"8-isoprostane F2\u03b1 up-regulates the expression of type 5 phosphodiesterase in cavernosal vascular smooth muscle cells: inhibition with sildenafil, iloprost, nitric oxide and picotamide","volume":"106","author":"Hotston","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2017.06.010_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1164\/rccm.200303-346OC","article-title":"A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats","volume":"169","author":"Itoh","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2017.06.010_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-4652(200101)186:1<1::AID-JCP1012>3.0.CO;2-D","article-title":"Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation","volume":"186","author":"Koyama","year":"2001","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib10","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1213\/01.ane.0000278736.81133.26","article-title":"The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1\/2 phosphorylation","volume":"105","author":"Li","year":"2007","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejphar.2017.06.010_bib11","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.109.906818","article-title":"Oxidative stress regulates left ventricular PDE5 expression in the failing heart","volume":"121","author":"Lu","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.06.010_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0022-3565(24)37102-2","article-title":"Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension","volume":"283","author":"Maclean","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.06.010_bib13","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.jacc.2015.03.540","article-title":"Management of pulmonary arterial hypertension","volume":"65","author":"McLaughlin","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib14","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.06.010_bib15","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib16","doi-asserted-by":"crossref","first-page":"L666","DOI":"10.1152\/ajplung.90548.2008","article-title":"Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension","volume":"297","author":"Ogawa","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study","volume":"60","author":"Oudiz","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0006-2952(02)00919-X","article-title":"Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery","volume":"63","author":"Pauvert","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/0960327111429138","article-title":"Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats","volume":"31","author":"Rashid","year":"2012","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/01.CIR.0000143836.40431.F5","article-title":"Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy","volume":"110","author":"Rondelet","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.06.010_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1254\/jphs.09110FP","article-title":"Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats","volume":"111","author":"Sawamura","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2017.06.010_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1164\/rccm.200302-282OC","article-title":"Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats","volume":"169","author":"Schermuly","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2017.06.010_bib23","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","volume":"107","author":"Sebkhi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.06.010_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09059180.00001713","article-title":"Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?","volume":"22","author":"Seferian","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejphar.2017.06.010_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12020-015-0586-x","article-title":"PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells","volume":"50","author":"Sponziello","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.ejphar.2017.06.010_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00395-004-0504-5","article-title":"Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells","volume":"100","author":"Tantini","year":"2005","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.athoracsur.2005.06.040","article-title":"Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression","volume":"81","author":"Tsai","year":"2006","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ejphar.2017.06.010_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1465-9921-10-123","article-title":"Inhibition of SOC\/Ca2+\/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells","volume":"10","author":"Wang","year":"2009","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2017.06.010_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1254\/jphs.08069FP","article-title":"Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry","volume":"108","author":"Wang","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2017.06.010_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2017.06.010_bib31","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.06.010_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1183\/09031936.00124007","article-title":"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension","volume":"32","author":"Wilkins","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2017.06.010_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCRESAHA.112.266361","article-title":"Enhanced Ca2+-sensing receptor function in idiopathic pulmonary arterial hypertension","volume":"111","author":"Yamamura","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2017.06.010_bib34","doi-asserted-by":"crossref","first-page":"e0138384","DOI":"10.1371\/journal.pone.0138384","article-title":"Inhibition of excessive cell proliferation by calcilytics in idiopathic pulmonary arterial hypertension","volume":"10","author":"Yamamura","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2017.06.010_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2016.04.059","article-title":"Calcilytics enhance sildenafil-induced antiproliferation in idiopathic pulmonary arterial hypertension","volume":"784","author":"Yamamura","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.06.010_bib36","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1073\/pnas.0405908101","article-title":"Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension","volume":"101","author":"Yu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2017.06.010_bib37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.06.010_bib38","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s12035-015-9293-0","article-title":"NF-\u03baB upregulates type 5 phosphodiesterase in N9 microglial cells: inhibition by sildenafil and yonkenafil","volume":"53","author":"Zhao","year":"2016","journal-title":"Mol. Neurobiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917304004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917304004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:04:20Z","timestamp":1750298660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917304004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"alternative-id":["S0014299917304004"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.06.010","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}